查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2045904

豬疫苗市場－全球產業規模、佔有率、趨勢、機會和預測：按產品、類型、目標疾病、地區和競爭格局分類，2021-2031年

Swine Vaccines Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Type, By Target Disease, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 177 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球豬疫苗市場預計將大幅擴張，從 2025 年的 13.9 億美元成長到 2031 年的 18.5 億美元，複合年成長率為 4.88%。

豬疫苗是一種旨在刺激豬的免疫系統並提供針對特定病原體的獲得性免疫的生物製藥。該市場的成長主要受全球豬肉消費量成長的驅動，而豬肉消費量的成長不僅源於高效畜牧生產的需求，也源於旨在降低通用感染疾病風險的日益嚴格的食品安全法規的實施。此外，人們對預防性獸醫學的日益關注（這對於最大限度地減少疾病爆發造成的經濟損失至關重要）也顯著提升了對這些免疫產品的需求。預計到2025年，全球豬肉產量將達到1.167億噸，這為確保畜群永續性所需的獸藥保健產品提供了巨大的市場潛力。然而，市場擴張的一大障礙是維護低溫運輸基礎設施的高成本和複雜的物流流程，而這些基礎設施對於有效儲存和分銷這些易碎的生物製藥至關重要，尤其是在新興經濟體中。

市場概覽
預測期 2027-2031
市場規模：2025年 13.9億美元
市場規模：2031年 18.5億美元
複合年成長率：2026-2031年 4.88%
成長最快的細分市場 重組疫苗
最大的市場 亞太地區

市場促進因素

豬病和通用感染疾病的跨境傳播是全球豬疫苗市場的主要促進因素。非洲豬瘟（ASF）和豬繁殖與呼吸綜合症（PRRS）等高致病性病原體的持續傳播迫使養殖戶實施嚴格的疫苗接種計劃，以保護牲畜健康和經濟永續性。這些疫情不僅擾亂國際貿易，而且對糧食安全構成重大威脅，因此必須立即採取獸醫干預措施，以防止牲畜數量出現災難性下降。例如，自2022年1月以來，已有71個國家報告了非洲豬瘟疫情，預計到2025年11月，將有超過220萬頭牲畜死亡。這凸顯了預防措施的重要性，並推動了全部區域對有效生物防治措施的持續需求。同時，為應對新型和變異病毒株，製藥公司加大研發投入，力求彌合免疫缺口並應對疫苗效力挑戰，這進一步加速了市場發展。業界領導企業正大力投資，擴大生產基礎設施和研究能力，以應對新出現的病毒變種並改善疫苗接種機制。一個顯著的例子是默克動物保健公司於2025年5月宣布的堪薩斯州8.95億美元擴建計劃，旨在加強其疫苗生產和研發能力。雖然資金籌措的激增正在加速下一代解決方案的研發，但其商業性成功仍與市場接受度密切相關。勃林格殷格翰的豬疫苗Ingelvac-Circoflex也印證了該領域的強勁投資和盈利，該產品在截至2025年4月的會計年度實現了2.15億歐元的年銷售額。

市場挑戰

維持低溫運輸基礎設施的高成本和複雜的物流流程嚴重阻礙了全球豬疫苗市場的擴張，尤其是在新興經濟體。豬疫苗是高度溫度敏感的生物製藥，必須保持從生產到接種的整個過程都處於不間斷的溫控儲存狀態。在生豬生產不斷擴張的發展中地區，可靠的電力供應和專業的物流網路往往匱乏，迫使經銷商承擔高昂的成本來防止產品劣化，從而推高了疫苗的最終價格。這種經濟負擔常常使許多小規模農戶難以負擔必要的獸醫服務，而小農戶正是目標市場的重要組成部分。因此，這種物流瓶頸限制了疫苗在高成長地區的市場滲透，儘管疾病控制迫在眉睫，卻有效地抑制了產生收入，並且與市場正努力緩解的持續生產力下降密切相關。根據聯合國糧食及農業組織（糧農組織）的估計，到2024年，跨國動物疫病將在全球造成約3,000億美元的經濟損失，約佔畜牧業總產值的20%。這項數據凸顯了巨大的市場缺口，基礎設施不足阻礙了免疫產品的有效供應，從而限制了該產業滿足全球需求的能力。

市場趨勢

非洲豬瘟（ASF）的研發正在加速推進，迅速從實驗階段邁向疫苗的商業性化應用，從根本上改變了流行地區的疾病控制方案。儘管生物安全措施仍然至關重要，但核准生物防治措施進入國際貿易市場正經歷歷史性的轉變，這主要是由於東南亞地區迫切需要保護現有的牲畜群。這一重大變化證明了科學界將重點放在活病毒疫苗平台上，以應對這種先前缺乏有效預防措施的複雜病毒威脅的合理性。例如，為了支持菲律賓的疾病管制工作，越南AVAC公司於2025年9月向菲律賓出口了第二批非洲豬瘟疫苗（34萬劑），顯示跨境市場對新配方疫苗的信心日益增強。同時，多價疫苗和聯合疫苗的研發正在重塑畜牧業健康管理策略，透過減少操作次數，優先考慮營運效率和動物福利。生產商正擴大採用多抗原配方，只需單劑即可同時抵禦多種病原體和多種病毒基因型，從而最大限度地減少壓力引起的生產力損失並降低人事費用。這一趨勢迫使製造商在其主要產品線中加入廣譜免疫，以應對在實際應用中觀察到的病毒株遺傳多樣性的變化。例如，勃林格殷格翰公司於2025年9月推出的Ingelvac Circoflex AD疫苗，就是一種突破性的聯合疫苗，專門針對PCV2a和PCV2d基因型，這兩種基因型佔臨床豬環狀病毒病例的90%以上。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球豬疫苗市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 產品分類（減毒活病毒疫苗、DNA疫苗、去活化疫苗、重組疫苗、次單位疫苗）
    • 依類型（胸膜肺炎放線桿菌、經典豬瘟、口蹄疫、豬環狀病毒2型、豬細小病毒、豬繁殖與呼吸綜合症病毒、偽狂犬病、豬流感）
    • 目標疾病（關節炎、博德氏菌鼻炎、腹瀉、口蹄疫、豬環狀病毒相關疾病、豬隻繁殖與呼吸症候群、疑似狂犬病、豬流感）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美豬疫苗市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲豬疫苗市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區豬疫苗市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲豬疫苗市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美豬疫苗市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球豬疫苗市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Merck & Co Inc
  • Zoetis Inc
  • Boehringer Ingelheim GmbH
  • Elanco Animal Health Inc
  • Indian Immunologicals Ltd
  • Biogenesis Bago SA
  • Phibro Animal Health Corp
  • Laboratorios HIPRA SA
  • Virbac SA

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 18799

The global swine vaccines market is set for considerable expansion, with projections indicating growth from USD 1.39 billion in 2025 to USD 1.85 billion by 2031, at a compound annual growth rate of 4.88%. Swine vaccines are biological preparations formulated to stimulate the immune system of pigs, thereby providing acquired immunity against specific pathogens. This market's growth is primarily propelled by the escalating global consumption of pork, which necessitates efficient livestock production, alongside the implementation of increasingly stringent food safety regulations aimed at controlling zoonotic risks. Furthermore, a heightened emphasis on preventative veterinary care, crucial for minimizing the financial losses associated with disease outbreaks, significantly boosts the demand for these immunization products. With global pork production forecast to reach 116.7 million metric tons in 2025, a vast addressable market exists for veterinary health products vital for ensuring herd sustainability. However, a notable impediment to market expansion lies in the high costs and logistical complexities involved in maintaining the cold chain infrastructure required for the effective storage and distribution of these sensitive biological products, particularly within emerging economies.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 1.39 Billion
Market Size 2031USD 1.85 Billion
CAGR 2026-20314.88%
Fastest Growing SegmentRecombinant Vaccines
Largest MarketAsia Pacific

Market Driver

The increasing prevalence of transboundary and zoonotic swine diseases serves as the primary catalyst propelling the global swine vaccines market forward. The persistent spread of high-impact pathogens, such as African Swine Fever (ASF) and Porcine Reproductive and Respiratory Syndrome (PRRS), compels producers to adopt rigorous immunization schedules to safeguard herd health and economic viability. These outbreaks not only disrupt international trade but also pose significant threats to food security, necessitating immediate veterinary intervention to prevent catastrophic stock depletion. For instance, African Swine Fever had been reported in 71 countries since January 2022, leading to over 2.2 million animal losses by November 2025, underscoring the critical reliance on prophylactic measures and driving sustained demand for effective biological countermeasures across major pork-producing regions. Concurrently, escalating R&D investments aimed at addressing novel and evolving viral strains further accelerate market development, as pharmaceutical companies endeavor to bridge gaps in immunity and vaccine efficacy. Industry leaders are channeling substantial capital into expanding manufacturing infrastructure and scientific capabilities to combat emerging variants and improve delivery mechanisms; a notable example is Merck Animal Health's announcement in May 2025 of an $895 million expansion in Kansas specifically to boost vaccine manufacturing and research capabilities. This surge in funding facilitates the creation of next-generation solutions, although their commercial success remains closely tied to market uptake. The robust financial commitment and returns in this sector are further illustrated by Boehringer Ingelheim's Ingelvac Circoflex swine vaccine, which achieved annual sales of 215 million EUR for the 2024 financial year by April 2025.

Market Challenge

The high cost and logistical complexity inherent in maintaining cold chain infrastructure significantly impede the expansion of the Global Swine Vaccines Market, especially within emerging economies. Swine vaccines are strictly temperature-sensitive biological products that require an unbroken chain of climate-controlled storage from the point of manufacture to administration. In developing regions, where pork production is intensifying, the prevalent absence of reliable electricity and specialized logistics networks forces distributors to incur exorbitant expenses to prevent product spoilage, thereby inflating the final cost of immunization. This financial burden often renders essential veterinary care economically inaccessible for many small-scale farmers, who constitute a crucial segment of the addressable market. Consequently, this logistical bottleneck restricts market penetration in high-growth geographic zones, effectively stalling revenue generation despite the urgent need for disease control, and correlating with sustained productivity losses that the market struggles to mitigate. According to the Food and Agriculture Organization, transboundary animal diseases were estimated to cause global economic losses of approximately USD 300 billion annually in 2024, representing a roughly 20 percent loss in total livestock production value; this data highlights the substantial market gap where infrastructure deficits prevent the effective delivery of immunization products, thereby hampering the industry's ability to capitalize on global demand.

Market Trends

Accelerated research and development for African Swine Fever (ASF) solutions is rapidly transitioning from experimental trials to the commercial deployment of viable immunizations, fundamentally altering disease management protocols in endemic regions. While biosecurity measures remain foundational, the market is witnessing the historic introduction of approved biological countermeasures into international trade, driven by the urgent necessity to protect standing herds, particularly in Southeast Asia. This significant shift validates the scientific community's focus on live attenuated platforms to combat complex viral threats that previously lacked effective prophylaxis; for instance, demonstrating growing cross-border trust in new formulations, AVAC Vietnam Joint Stock Company exported a second batch comprising 340,000 doses of its African Swine Fever vaccine to the Philippines in September 2025 to support the country's disease control efforts. Simultaneously, the development of multivalent and combination vaccines is reshaping herd health strategies by prioritizing operational efficiency and animal welfare through reduced handling. Producers are increasingly adopting multi-antigen formulations that allow for simultaneous protection against diverse pathogens or multiple viral genotypes in a single administration, thereby minimizing stress-induced performance dips and lowering labor costs. This trend is compelling manufacturers to integrate broader coverage into their flagship product lines to match the evolving genetic diversity of field strains, as illustrated by Boehringer Ingelheim's September 2025 launch of Ingelvac Circoflex AD, a novel combination vaccine specifically engineered to target the PCV2a and PCV2d genotypes responsible for over 90 percent of clinical porcine circovirus cases.

Key Market Players

  • Merck & Co Inc
  • Zoetis Inc
  • Boehringer Ingelheim GmbH
  • Elanco Animal Health Inc
  • Indian Immunologicals Ltd
  • Biogenesis Bago SA
  • Phibro Animal Health Corp
  • Laboratorios HIPRA SA
  • Virbac SA

Report Scope

In this report, the Global Swine Vaccines Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Swine Vaccines Market, By Product

  • Attenuated Live Vaccines
  • DNA Vaccines
  • Inactivated Vaccines
  • Recombinant Vaccines
  • Subunit Vaccines

Swine Vaccines Market, By Type

  • Actinobacillus Pleuropneumoniae
  • Classical Swine Fever
  • Foot & Mouth Disease
  • PEDV
  • Porcine Circovirus Type 2
  • Porcine Parvovirus
  • PRRS
  • Pseudorabies
  • Swine Influenza

Swine Vaccines Market, By Target Disease

  • Arthritis
  • Bordetella Rhinitis
  • Diarrhea
  • Foot & Mouth Disease
  • Porcine Circovirus Associated Disease
  • Porcine Reproductive & Respiratory Syndrome
  • Pseudorabies
  • Swine Influenza

Swine Vaccines Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Swine Vaccines Market.

Available Customizations:

Global Swine Vaccines Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Swine Vaccines Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Attenuated Live Vaccines, DNA Vaccines, Inactivated Vaccines, Recombinant Vaccines, Subunit Vaccines)
    • 5.2.2. By Type (Actinobacillus Pleuropneumoniae, Classical Swine Fever, Foot & Mouth Disease, PEDV, Porcine Circovirus Type 2, Porcine Parvovirus, PRRS, Pseudorabies, Swine Influenza)
    • 5.2.3. By Target Disease (Arthritis, Bordetella Rhinitis, Diarrhea, Foot & Mouth Disease, Porcine Circovirus Associated Disease, Porcine Reproductive & Respiratory Syndrome, Pseudorabies, Swine Influenza)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Swine Vaccines Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Type
    • 6.2.3. By Target Disease
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Swine Vaccines Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Type
        • 6.3.1.2.3. By Target Disease
    • 6.3.2. Canada Swine Vaccines Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Type
        • 6.3.2.2.3. By Target Disease
    • 6.3.3. Mexico Swine Vaccines Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Type
        • 6.3.3.2.3. By Target Disease

7. Europe Swine Vaccines Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Type
    • 7.2.3. By Target Disease
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Swine Vaccines Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Type
        • 7.3.1.2.3. By Target Disease
    • 7.3.2. France Swine Vaccines Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Type
        • 7.3.2.2.3. By Target Disease
    • 7.3.3. United Kingdom Swine Vaccines Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Type
        • 7.3.3.2.3. By Target Disease
    • 7.3.4. Italy Swine Vaccines Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Type
        • 7.3.4.2.3. By Target Disease
    • 7.3.5. Spain Swine Vaccines Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Type
        • 7.3.5.2.3. By Target Disease

8. Asia Pacific Swine Vaccines Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Type
    • 8.2.3. By Target Disease
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Swine Vaccines Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Type
        • 8.3.1.2.3. By Target Disease
    • 8.3.2. India Swine Vaccines Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Type
        • 8.3.2.2.3. By Target Disease
    • 8.3.3. Japan Swine Vaccines Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Type
        • 8.3.3.2.3. By Target Disease
    • 8.3.4. South Korea Swine Vaccines Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Type
        • 8.3.4.2.3. By Target Disease
    • 8.3.5. Australia Swine Vaccines Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Type
        • 8.3.5.2.3. By Target Disease

9. Middle East & Africa Swine Vaccines Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Type
    • 9.2.3. By Target Disease
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Swine Vaccines Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Type
        • 9.3.1.2.3. By Target Disease
    • 9.3.2. UAE Swine Vaccines Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Type
        • 9.3.2.2.3. By Target Disease
    • 9.3.3. South Africa Swine Vaccines Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Type
        • 9.3.3.2.3. By Target Disease

10. South America Swine Vaccines Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Type
    • 10.2.3. By Target Disease
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Swine Vaccines Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Type
        • 10.3.1.2.3. By Target Disease
    • 10.3.2. Colombia Swine Vaccines Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Type
        • 10.3.2.2.3. By Target Disease
    • 10.3.3. Argentina Swine Vaccines Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Type
        • 10.3.3.2.3. By Target Disease

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Swine Vaccines Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Merck & Co Inc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Zoetis Inc
  • 15.3. Boehringer Ingelheim GmbH
  • 15.4. Elanco Animal Health Inc
  • 15.5. Indian Immunologicals Ltd
  • 15.6. Biogenesis Bago SA
  • 15.7. Phibro Animal Health Corp
  • 15.8. Laboratorios HIPRA SA
  • 15.9. Virbac SA

16. Strategic Recommendations

17. About Us & Disclaimer